CD8A and neoplasm: Particularly, twofold or greater CD8+ TIL influx was only observed in patients with confirmed tumor-site TIM-3 decrease (p=0.015, figure 5A), consistent with the TIM-3 checkpoint limiting CD8+ T-cell responses.